RE:RE:RE:Corporate Presentation Updated with some guidanceI'd like to know more about the meetings (and subsequent continuing education program) TRX had with the Canadian Headache Society regarding the new communication strategy surrounding the new CHS migraine treatement guidelines. Looks like Cambia perscriptions really took off in March after they rolled them out to key opinion leaders.
Eyeballing their graph, it looks like Q1 has around a 15% increase in Cambia perscriptions over Q4 14 and, as stated, a 37% increase month over month from Feb to March. If the KOL poll numbers are to be believed, and March wasn't a fluke, Cambia might be poised to rack up some monster sales numbers here in the coming months.
Efforts such as these communications strategies shouldn't be underestimated by the company. Frankly, I wish they would have said something about these initiatives (and others like them?) before Burton and Bloom, at least publically. It means management isn't just out there promoting their products, but driving their adoption through established institutions. Looking forward to Q1 numbers! Glta.